Successful Med-Tech Veteran Joins Board of Tenex Health

LAKE FOREST, Calif.--(BUSINESS WIRE)--Tenex Health, a pioneer in image-guided soft tissue repair, is pleased to announce the appointment of Doug Kohrs to the company's board of directors.

Doug brings more than 30 years of experience in medical devices with 20 of those years spent as a founder or CEO for several innovative medical device companies. In addition to his contributions as CEO, over the past 15 years he has served on the board of directors of 10 diverse medical technology companies. He was most recently CEO and President of Tornier, a premier orthopedics company which he guided from a family-owned business to a global player in the joint replacement and soft tissue repair markets. Prior to Tornier, Doug was CEO of American Medical Systems where he turned a small urological-products firm into a successful public company. Before that, he was one of the founders of Spine-Tech, an orthopedic manufacturer later acquired by global medical technology giant Sulzer.

"Doug's experience and serial achievements in taking strong businesses and making them even better is invaluable," said Jagi Gill, CEO of Tenex Health. "We are extremely fortunate to have him as part of our board of directors and look forward to the incredible operational and strategic insight that we know he will add to Tenex during this significant time of growth in our company."

Tenex has experienced a successful launch of its first product line addressing joint pain associated with tendon damage. The company's proprietary technology utilizes a minimally invasive system to perform a percuatneous tenotomy or fasciotomy which addresses a global market of over 20 million patients each year suffering from chronic tendonosis. A clinically compelling success rate of pain relief with the out-patient procedure has been complimented by a rapid adoption of the system by over 200 physicians in the US.

"The compelling therapy inherent in the technology platform developed by Tenex addresses the new realities of our healthcare system. This new technology offers a minimally invasive and cost effective solution that gives patients the opportunity to quickly return to their previous work and activity levels," said Doug. "I look forward to contributing to the strategic growth of this technology and providing guidance towards the development of new treatment modalities. I am confident in the company's bright future."

Ivan Mijatovic, Chairman of the Board of Tenex Health added, "Doug has demonstrated success and delivered impressive growth for all of the companies he has been involved with. We are delighted and honored to have him provide his experience and strategic guidance to Tenex at this important time of the company's rapid growth."

About Tenex Health Inc. Tenex Health, Inc. ( develops and markets innovative therapies for the treatment of tendon pain due to trauma or repetitive motion injuries. These tendon injuries affect more than 10 million persons in the US alone every year. The company's proprietary TX1 Tissue Removal System is used to safely and specifically cut and debride diseased soft tissue in an outpatient setting using only local anesthetic ( Since the surrounding healthy tendon tissue is not disturbed, patients enjoy less discomfort and faster recovery times versus traditional open surgical procedures. The one-time procedure is usually completed within 20 minutes and with no need for follow-up treatments.

Suggested Articles

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.

The new parliamentary arithmetic gives Boris Johnson the numbers to pass the withdrawal agreement and take the U.K. out of the EU.

The discovery that 500 cancers can be slotted into 10 subtypes, each of which is driven by a common set of proteins, could inspire new therapies.